Radiodermatitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Radiodermatitis – Drugs In Development, 2024 report and make more profitable business decisions.
Radiodermatitis is an inflammation of the skin caused by radiation. Several treatment factors can be attributed to the varying response of the patients’ skin to radiation therapy; individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.
The Radiodermatitis drugs in development market research report provide comprehensive information on the therapeutics under development for Radiodermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Radiodermatitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 19 molecules, with 18 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Radiodermatitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Radiodermatitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Radiodermatitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Allander Biotechnologies LLCBeijing Puqi Pharmaceutical Technology Co Ltd
BioCurity Pharmaceuticals Inc
Chiesi Farmaceutici SpA
Clevexel Pharma SA
Devonian Health Group Inc
DMK Pharmaceuticals Corp
Foresee Pharmaceuticals Co Ltd
Lutris Pharma
Neuropathix Inc
Noveome Biotherapeutics Inc
NYU Langone Health System
Perpetuum BV
Regeneus Ltd
RepoCeuticals ApS
Sunny Pharmtech Inc
VasoDynamics Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Radiodermatitis reports